Stejbach Mark 4

What Happened
Mark Stejbach, a director of Indivior Pharmaceuticals, was granted 3,722 restricted stock units (RSUs) on January 26, 2026. The grant is reported at a $0.00 acquisition price, reflecting that these are compensatory RSUs rather than a market purchase. The Form 4 disclosing the grant was filed on January 28, 2026.

Key Details

• Transaction date: 2026-01-26 (reported on Form 4 dated 2026-01-28)
• Transaction type/code: Award/Grant (A) — 3,722 RSUs granted at $0.00 per unit
• Total reported acquisition value: $0 (grant of RSUs, not a cash purchase)
• Shares owned after transaction: not disclosed in the provided filing excerpt
• Footnote: Each RSU is a contingent right to one share; they vest on the day immediately preceding the Issuer's first annual stockholders' meeting after the grant date, subject to Stejbach’s continued service.

Context
RSU grants are a common form of director/executive compensation and do not represent an open-market purchase or sale. Because vesting is conditional on continued service, these RSUs don't transfer shares immediately and are not an immediate liquidity event. This filing is informational about compensation; it does not by itself indicate insider buying or selling sentiment.